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SUMMARY 
Activating mutations in NRAS account for 20-30% of melanoma, but despite decades of research and in 
contrast to BRAF, no effective anti-NRAS therapies have been forthcoming. Here we identify a previously 
uncharacterized serine/threonine kinase STK19 as a novel NRAS activator. STK19 phosphorylates NRAS 
to enhance its binding to its downstream effectors and promotes oncogenic NRAS-mediated melanocyte 
malignant transformation. A recurrent D89N substitution in STK19 whose alterations were identified in 
25% of human melanomas represents a gain-of-function mutation that interacts better with NRAS to 
enhance melanocyte transformation. STK19D89N knockin leads to skin hyperpigmentation and promotes 
NRASQ61R-driven melanomagenesis in vivo. Finally, we developed ZT-12-037-01 (1a) as a specific 
STK19-targeted inhibitor and showed that it effectively blocks oncogenic NRAS-driven melanocyte 
malignant transformation and melanoma growth in vitro and in vivo. Together, our findings provide a new 
and viable therapeutic strategy for melanomas harboring NRAS mutations. 
 
 
 
 
 
 
 
 
 
 
  
INTRODUCTION 
RAS proteins are small membrane-bound guanine nucleotide-binding GTPases, acting as molecular 
switches by converting between GDP-bound inactive state and GTP-bound active state (Bos, 1989; 
Downward, 2003; Milburn et al., 1990; Pylayeva-Gupta et al., 2011). They play a central role in the 
regulation of cell proliferation, differentiation and survival by activating different downstream signaling 
pathways including RAF-MEK-ERK and PI3K-AKT pathways (Downward, 2003; Lavoie and Therrien, 
2015; Mendoza et al., 2011; Samatar and Poulikakos, 2014). The RAS family has three major isoforms, 
KRAS, HRAS and NRAS (Barbacid, 1987; Malumbres and Barbacid, 2003) that share 92-98% sequence 
identity in the amino-terminal 1-165 residues but substantially diverge in the carboxy-terminal 23-24 
residues of hypervariable region (HVR) (Krengel et al., 1990; Prior et al., 2012). Oncogenic mutations of 
RAS family members are commonly found in 20% to 30% of all human tumors (Prior et al., 2012; Stephen 
et al., 2014). Despite the highly conserved sequence similarity, the three major RAS isoforms exhibit 
distinct preferences in coupling to particular cancer types (Pylayeva-Gupta et al., 2011; Stephen et al., 
2014). For instance, oncogenic mutations of KRAS are most identified in pancreatic ductal 
adenocarcinomas (PDAC) and colorectal adenocarcinomas (CRC) (Cox et al., 2014), HRAS mutations 
are frequently associated with bladder cancer (Cox et al., 2014; Prior et al., 2012), whereas NRAS 
mutations occur most frequently in cutaneous melanomas and acute myeloid leukemia (Bacher et al., 2006; 
Goel et al., 2006; Prior et al., 2012).   
   The prevailing NRAS mutation in melanoma occurs at position 61, where glutamine is substituted by 
arginine/lysine/leucine (Q61R/K/L) (Bos, 1989; Hayward et al., 2017; Jakob et al., 2012). This mutation 
impairs the intrinsic GTP hydrolysis activity and traps NRAS in a constitutive GTP-bound active 
conformation, which recruits RAF to the inner membrane for dimerization and activation (Marais et al., 
1995; Smith et al., 2013). The most frequent mutation of BRAF (approximately 90%) is the substitution 
of valine to glutamate at position 600 (Davies et al., 2002). The BRAFV600E mutation increases its kinase 
activity more than 10.7-fold and stimulates constitutive activation of the downstream MEK-ERK signaling 
(Davies et al., 2002; Wan et al., 2004; Wellbrock et al., 2004). The oncogenic activation of NRAS and 
BRAF leads to growth factor-independent proliferation of melanocytes and finally transformation to 
melanoma (Davies et al., 2002; Ji et al., 2012). Thus, NRAS Q61 mutations and BRAFV600E mutation are 
key drivers of melanomagenesis and important therapeutic targets. Unlike the well-defined BRAF 
inhibitors, the development of direct NRAS-selective inhibitors has been unsuccessful in the past decades 
(Cox et al., 2014).  
   Oncogenic activity of RAS depends on its localization at the inner face of the plasma membrane and its 
subsequent association with major effectors for downstream signal transduction, which are modulated by 
RAS posttranslational modifications including prenylation, palmitoylation and phosphorylation (Ahearn 
et al., 2011; Barcelo et al., 2013; Berndt et al., 2011; Chiu et al., 2002; Jackson et al., 1990). Prenylation 
at the CAAX box cysteine and addition of a palmitic moiety to a second cysteine residue in the C-terminal 
hypervariable region (HVR) result in hydrophobic anchors to localize RAS to the plasma membrane (Buss 
and Sefton, 1986; Casey et al., 1989; Wright and Philips, 2006). RAS phosphorylation at different sites 
also distinctly regulates RAS activity. Phosphorylation at tyrosine 32 by SRC promotes the intrinsic 
GTPase activity of RAS to downregulate RAS signaling pathway (Bunda et al., 2014), whereas 
phosphorylation at tyrosine 137 by ABL allosterically enhances the binding of RAS to RAF (Ting et al., 
2015).  Phosphorylation at serine 181 of oncogenic KRAS is required for tumor growth and apoptosis 
inhibition (Barcelo et al., 2014). Therefore, targeting the regulators of RAS modification may provide a 
novel perspective to develop anti-RAS therapies for cancer treatment.  
   The human STK19 gene (also named as G11 or RP1) localizes in the class III region of the major 
histocompatibility complex (MHC) (Sargent et al., 1994). STK19 protein consists of 368 amino acids and 
two major functional domains: the regulatory domain (1-110 aa) and the catalytic kinase domain (111-
368 aa) (Gomez-Escobar et al., 1998). STK19 was originally reported to phosphorylate α-casein at 
serine/threonine residues and histones at serine residues (Gomez-Escobar et al., 1998). Recently, it has 
been reported to involve in transcription-related DNA damage response (Boeing et al., 2016). However, 
the role of STK19 in cancer initiation and development is poorly appreciated. Importantly, STK19 harbors 
significant somatic hot spot mutations in 5% of melanoma (Hodis et al., 2012) and 10% of skin basal cell 
carcinoma (Bonilla et al., 2016) respectively, and is listed among the top melanoma driver genes 
(Lawrence et al., 2014). This strong genetic evidence implies an important, but uncharacterised role of 
STK19 in melanocyte malignant transformation and melanoma progression. 
   In this study, we set out to use melanoma as a model to identify novel strategies for targeting oncogenic 
RAS signaling by identifying kinases that regulate NRAS activity and leading to the discovery of STK19. 
We demonstrated that STK19 phosphorylates NRAS at serine 89, and consequently enhanced binding 
between NRAS and its effectors and activated NRAS downstream signaling pathways to induce 
melanocyte malignant transformation. We also showed that the frequent D89N substitution detected in 
melanoma patients represents a gain-of-function mutation in STK19 that in knock-in mice causes skin 
hyperpigmentation and promotes oncogenic NRAS-driven melanomagenesis. By developing a specific 
and novel STK19-targeted inhibitor, ZT-12-037-01 (1a), we were able to effectively blockade oncogenic 
NRAS-driven melanocyte malignant transformation and melanoma growth. Our results reveal how 
targeting STK19 may provide an effective therapeutic strategy for NRAS mutant melanomas. 
 
RESULTS 
STK19 is a critical regulator of NRAS function  
Activation of NRAS signaling depends on its association with effector proteins, such as RAF and PI3K, 
that contain a common RAS-binding domain (RBD) (Pylayeva-Gupta et al., 2011). Disrupting the NRAS-
RBD protein interaction would represent an effective therapy in NRAS mutant melanoma. To achieve this 
objective, we screened for kinases that could regulate the activity of NRASQ61R, the most prevalent NRAS 
mutation found in melanoma (Jakob et al., 2012). We therefore established HEK293FT cells expressing 
HA-tagged NRASQ61R and screened a primary human kinome siRNA library using a modified active 
NRAS chemiluminescence assay as a readout. Specifically, HA-NRASQ61R from siRNA-transfected cells 
was captured using a GST-CRAF-RBD fusion protein on glutathione-coated plates, and detected with an 
anti-HA tag antibody conjugated with horseradish peroxidase for luminescence quantification (Figure 
1A). We initially identified 12 kinases whose knockdown led to more than 50% inhibition of NRASQ61R 
activity, and six kinases whose knockdown led to at least two-fold upregulation of NRASQ61R activity 
(Figure 1B). Among these genes, EGFR, SYK and SRC are well-known regulators of NRAS functions 
(Bunda et al., 2014; Downward, 2003; Kawakami et al., 2003). However, of all the hits, STK19 was one 
of the candidates whose knockdown caused the highest inhibition on NRAS activity (35.1% of control 
group) (Figure 1B). To identify the status of STK19 in human melanomas, we investigated STK19 
alteration in the TCGA melanoma cohort (PanCancer Atlas) and found STK19 to be altered in 91 of 363 
(25.07%) sequenced skin cutaneous melanoma cases (Figure 1C). This is consistent with the analysis of 
large-scale melanoma exome data that discovered STK19 as one of six novel melanoma genes (PPP6C, 
RAC1, SNX31, TACC1, STK19, and ARID2) with a statistically significant functional mutation burden 
(Hodis et al., 2012). As such, STK19 has been listed as an oncogenic candidate among the Broad Institute 
melanoma driver genes (Lawrence et al., 2014). Analysis of STK19 alteration in melanomas collected in 
different cBioPortal for Cancer Genomics databases further confirmed this discovery (Berger et al., 2012; 
Hodis et al., 2012; Hugo et al., 2016). However, the function of STK19 is largely uncharacterized, 
particularly in melanoma initiation and progression. We found that STK19 alteration was significantly 
mutually exclusive with BRAF in human melanomas (P=0.002) (Figure S1A), consistent with BRAF 
lying downstream from NRAS activation (Lavoie and Therrien, 2015). Given these observations, we 
further investigated the potential role of STK19 in regulating NRAS functions in melanomas.  
   Oncogenic NRAS plays a critical role in melanoma cell growth, which is mediated by its downstream 
signaling pathways including RAF-MEK-ERK and PI3K-AKT pathways (Ji et al., 2012). To confirm 
whether STK19 knockdown inhibits NRAS activity, we investigated whether the downstream signaling 
of NRAS was inhibited after STK19 silencing. Retroviruses encoding empty HA, HA-tagged wild-type 
NRAS or NRASQ61R were introduced into human primary melanocytes (HPMs) depleted of STK19. The 
active-RAS pull-down assay indicated that depletion of STK19 markedly decreased the active fraction of 
both wild type and oncogenic NRAS, and that consequently signaling downstream from NRAS via the 
RAF-MEK-ERK and PI3K-AKT pathways was diminished (Figure 1D). We also used melanoma cells 
with different NRAS mutation status to identify the role of STK19 in regulating endogenous NRAS. To 
this end, STK19 was silenced in A375 and UACC62 cells, both with BRAFV600E and wild-type NRAS, or 
SK-MEL-2 and WM2032 cells that both express NRASQ61R and wild-type BRAF (Barretina et al., 2012; 
Herlyn et al., 1985). Interestingly, inhibition of active NRAS and its downstream effectors (p-MEK, p-
ERK1/2, p-AKT) was highly efficient in SK-MEL-2 and WM2032 (NRASQ61R, BRAFWT) cells, but the 
inhibition was much weaker in A375 and UACC62 (BRAFV600E, NRASWT) cells (Figure S1B). 
Consistently, depletion of STK19 significantly decreased the growth rate of SK-MEL-2 and WM2032 
(NRASQ61R, BRAFWT) cells, but had a much smaller effect on the BRAFV600E, NRASWT cells or primary 
melanocytes (Figure S1C). To confirm that inhibition of NRAS signaling was mediated by STK19 
knockdown, two new sets of STK19-targeted shRNA were exploited and the resulting depletion of STK19 
notably inhibited NRAS activity and its downstream signaling in SK-MEL-2 and WM2032 cells (Figures 
S1D and S1E). Furthermore, we performed rescue experiments and infected the STK19-depleted 
melanoma cells with retroviruses encoding empty Flag or Flag-tagged STK19. The ectopic expression of 
STK19-Flag restored the activation of NRAS signaling (Figure S1F), confirming that the inhibition of 
NRAS signaling using STK19-specific shRNAs was mediated by knockdown of STK19 rather than the 
off-target effects. Collectively, these results suggest that STK19 has a crucial role in activating oncogenic 
NRASQ61R -driven signaling. 
   To explore the potential role of STK19 in NRASQ61R-driven tumorigenesis, the role of STK19 in 
melanocyte proliferation and malignant transformation was evaluated using genetically engineered human 
immortalized melanocytes (hTERT/p53DD/CDK4(R24C)) (Lissanu Deribe et al., 2016) expressing 
NRASQ61R together with STK19 silencing. The results indicated that silencing STK19 (Figure S1G) 
substantially inhibited the colony formation capacity of NRASQ61R-transformed melanocytes (Figure 1E), 
as well as their proliferation (Figure S1H) and tumor-forming ability in xenografts (Figures 1F-1H). 
These results suggest that STK19 is critical for NRASQ61R-driven melanomagenesis.  
 
STK19 phosphorylates NRAS protein at serine 89 
To identify the direct substrates of STK19, cell lysates collected from SK-MEL-2 cells expressing 
human recombinant Flag-tagged STK19 protein were purified using anti-Flag beads and the interaction 
factors analyzed by liquid chromatography/tandem mass spectrometry (LC-MS/MS) to identify STK19-
interacting proteins (Figure S2A). NRAS was identified as one of the most abundant STK19-interacting 
proteins on the basis of total number of unique peptides (13) (Figure 2A). Reciprocal co-
immunoprecipitation confirmed that endogenous STK19 strongly interacted with NRAS in SK-MEL-2 
and WM2032 cells (NRASQ61R), but bound less well in A375 and UACC62 cells (expressing wild type 
NRAS) (Figures S2B and S2C). The NRASQ61R-STK19 interaction was confirmed by reciprocal co-
immuno-precipitation from HPMs exogenously expressing STK19-Flag and HA-NRAS WT or Q61R 
mutant (Figures 2B and 2C). These results indicate that STK19 directly interacts with NRAS, and 
especially with NRASQ61R. 
   To address the significance of the STK19-NRASQ61R interaction, we asked whether NRAS was an 
STK19 substrate. Phosphorylated-serine, -threonine and -tyrosine in NRAS were detected in cellular 
lysates collected from HPMs expressing ectopic STK19 and NRAS (WT or Q61R) after NRAS 
immunoprecipitation (Figure 2D). Strikingly, serine, but not threonine or tyrosine phosphorylation of 
NRASQ61R mutant was substantially increased by STK19 expression, and only a marginal increase in 
phosphorylation of NRASWT was detected. We also observed robust endogenous NRAS phosphorylation 
in a panel of melanoma cells expressing NRASQ61R (Figure S2D) whereas phosphorylation of NRAS at 
serine residues was barely detectable in cells following STK19 silencing (Figures S2E and S2F). The 
upregulation of phosphorylated serine levels in NRAS was also diminished by overexpression of a kinase-
dead STK19 K317P mutant (Gomez-Escobar et al., 1998) (Figures S2G and S2H). These results suggest 
that STK19 phosphorylates NRAS at serine residues. 
   The preferential phosphorylation of NRASQ61R compared to NRASWT was also observed using an in 
vitro kinase assay (Figure S2I), suggesting that STK19 has a stronger preference towards GTP-loaded 
active NRAS. To verify this, we further performed an in vitro kinase assay using purified NRAS 
recombinant protein preloaded with GDP, GTP or GTPγS in the presence of recombinant STK19. We 
found a higher STK19-induced phosphorylation of the GTP- and GTPγS-loaded NRAS than GDP-loaded 
NRAS (Figure S2J). This was confirmed in experiments that showed STK19-induced phosphorylation of 
different NRAS mutant isoforms was more efficient than that of NRASWT (Figure S2K).  
   To identify the specific NRAS serine residue(s) phosphorylated by STK19, we performed mass 
spectrometry after in vitro phosphorylation of recombinant NRASQ61R by purified recombinant STK19 
protein. This approach identified phosphorylation of the evolutionarily conserved NRAS serine 89 (S89) 
(Figures 2E and 2F). In agreement with this observation, mutation of S89 to alanine (S89A) abolished 
phosphorylation of NRASWT and NRASQ61R (Figure 2G). 
   To confirm that STK19 upregulates NRAS activity through phosphorylating NRAS protein at S89, HA-
NRASWT, HA-NRASS89A, HA-NRASQ61R or HA-NRASQ61R/S89A were expressed in HPMs expressing 
ectopic STK19-Flag. After immunoprecipitation of NRAS WT or mutants, immunoblots were performed 
to detect interactions between NRAS and its effectors, including BRAF, CRAF and PI3Kα.  We found 
that STK19 overexpression dramatically enhanced the interaction between NRASQ61R and its effectors, 
and also stimulated signaling downstream of NRAS as detected by immunoblotting whole cell extracts 
(Figure 2H). No effects of STK19 were observed on a phosphorylation-defective form of NRAS 
(NRASS89A) or its signaling.  By contrast, the introduction of phosphomimetic NRASQ61R/S89D enhanced 
NRAS interaction with its effectors and its downstream signaling (Figure S2L). These data strongly 
suggest that STK19-regulated NRASQ61R activity is largely dependent on the phosphorylation at NRAS 
S89. Using HPMs expressing NRASWT, NRASQ61R and NRASQ61R/S89A mutants alone or together with 
STK19 (Figure S2M) revealed that STK19-stimulated NRAS-driven melanocyte proliferation and 
malignant transformation were inhibited by the NRAS S89A mutation in assays for colony formation 
(Figure 2I), cell proliferation (Figure S2N), and xenograft tumor assays (Figures 2J-2L). Moreover, 
mutation of S89 to phosphomimetic aspartate in the NRASQ61R mutant (Figure S2O) strongly promoted 
melanocyte colony formation (Figure S2P), proliferation (Figure S2Q) and tumor formation (Figures 
S2R-S2T). Taken together, our data indicate that STK19-mediated phosphorylation of NRAS at S89 
activates oncogenic NRAS-driven melanomagenesis. 
 
STK19 D89N is a recurrent gain-of-function mutation  
STK19 has a statistically significant mutation burden in melanoma, and a total of 19 mutations were 
identified in the TCGA melanoma database as of December of 2017. Strikingly, 8 of them (~42%) were 
the same mutation (D89N), and most of the other mutations were adjacent to this region (Figure 3A), 
suggesting STK19 D89 is a dominant mutant site in melanoma. These findings are consistent with Hodis 
et al’s exon sequence discovery that STK19 is an important cancer gene with a hot spot mutation pattern 
in melanoma (Hodis et al., 2012). We have shown that STK19 phosphorylates NRAS to activate its 
downstream signaling (Figures 1 and 2). However, it remained unclear how the STK19D89N might affect 
NRAS protein modification and activation. We therefore performed an in vitro kinase assay to compare 
the activity of STK19WT and STK19D89N mutant. We found that phosphorylation of purified recombinant 
NRAS was enhanced by STK19D89N to a higher extent than by STK19WT (Figure 3B). Accordingly, 
compared to STK19WT, the STK19D89N mutant co-immunoprecipitated more efficiently with NRAS, 
enhanced NRAS phosphorylation and activated higher NRAS downstream signaling (Figures 3C, S3A 
and S3B), and also promoted proliferation of SK-MEL-2 and WM2032 melanoma cells (Figure S3C). 
These data suggest that the recurrent STK19D89N mutation represents a gain-of-function mutation that 
operates by enhancing NRAS signaling.  
   To identify the role for STK19D89N in driving melanocyte malignant transformation, STK19D89N was 
expressed in human immortalized primary melanocytes (hTERT/p53DD/CDK4(R24C)) expressing wild 
type or mutant NRAS with endogenous STK19 silenced (Figure S3D) and the resulting cells assayed for  
colony formation, proliferation and tumor formation. The results revealed that in the presence of 
oncogenic NRASQ61R, STK19D89N significantly promoted melanocyte colony formation (Figure 3D), 
proliferation (Figure S3E) and tumor formation (Figures 3E-3G). Collectively these data indicate that 
STK19D89N, a gain-of-function mutation, contributes to melanomagenesis in the presence of activated 
NRAS.  
 STK19 D89N induces melanomagenesis in the presence of oncogenic NRAS in vivo  
To better understand the role of STK19 in melanocytes and melanomagenesis in vivo, we generated 
STK19WT or STK19D89N CRISPR-knockin mice.  cDNA encoding human STK19WT or STK19D89N was 
subcloned into a CRISPR/Cas9-mediated homologous recombination vector targeting the ROSA26 locus 
and injected into single-cell embryos of C57BL/6J mice (Chu et al., 2016). The exogenous transcription 
of the knockin alleles was controlled by using the CAG hybrid promoter. To spatiotemporally control 
knockin gene expression, a loxP-flanked transcriptional stop element was placed downstream of the CAG 
promoter (Figure S4A). The ROSA26 locus targeting of STK19WT and STK19D89N allele was confirmed 
by PCR (Figure S4B). Both STK19WT and STK19D89N knockin mice develop normally. The knockin mice 
with correct insertion were further intercrossed with the Tyr-CreERT2 mouse strain expressing Cre 
recombinase directed by the melanocyte-specific tyrosinase promoter/enhancer to achieve Tyr-Cre-
STK19WT and Tyr-Cre-STK19D89N mice and the expression of STK19WT and STK19D89N protein was 
confirmed by immunoblotting (Figure S4C). Remarkably, the Tyr-Cre-STK19D89N mice, but not the 
STK19WT mice, exhibited hyperpigmentation of the skin, ears and tail, and the melanin content in skin 
was significantly increased after tamoxifen induction (Figures 4A-4E), similar to the hyperpigmentation 
observed when oncogenic NRAS is targeted to the melanocyte lineage (Ackermann et al., 2005; Burd et 
al., 2014b).  
   To determine whether the overexpression of STK19WT and STK19D89N contributes to melanomagenesis 
in the presence of oncogenic NRASQ61R, Tyr-Cre-STK19WT or -STK19D89N mice were crossed with 
loxP/STOP/loxP NRASQ61R knockin (LSL-NRASQ61R) mice (Ackermann et al., 2005; Burd et al., 2014a) 
to generate Tyr-Cre-NRASQ61R-STK19WT or Tyr-Cre-NRASQ61R-STK19D89N knockin mice. The effects 
of STK19WT or STK19D89N knockin in activating NRAS signaling pathways were detected and confirmed 
by immunoblot analysis of primary mouse melanocytes derived from the relevant engineered mice. The 
results obtained using antibodies to detect phosphorylated ERK1/2 and AKT indicated that STK19, and 
especially the STK19 D89N mutant, enhanced oncogenic NRAS signaling (Figure 4F). By observing 
melanoma incidence and other skin abnormalities after tamoxifen induction for one year (Figure S4D), 
we found that exogenous expression of STK19WT and STK19D89N accelerated initiation and incidence of 
melanoma in NRASQ61R knockin mice (Figure 4G). Specifically, melanoma was first diagnosed 295, 211 
and 166 days after the tamoxifen injection in Tyr-Cre-NRASQ61R, Tyr-Cre-NRASQ61R-STK19WT and Tyr-
Cre-NRASQ61R-STK19D89N knockin mice, respectively. Significantly, melanoma was diagnosed in 78.9% 
of Tyr-Cre-NRASQ61R-STK19D89N knockin mice and 47.4% of Tyr-Cre-NRASQ61R-STK19WT mice 
(P=0.0269) compared to 11.1% of Tyr-Cre-NRASQ61R mice (P<0.001 and P=0.0116, respectively). Thus, 
the STK19D89N mutation increased melanoma incidence 7-fold on the NRASQ61R background versus 
NRASQ61R alone. The melanoma tissues from Tyr-Cre-NRASQ61R, Tyr-Cre-NRASQ61R-STK19WT, and 
Tyr-Cre-NRASQ61R-STK19D89N mice were also collected for immunoblot analysis to investigate activities 
of NRAS signaling. The results revealed that STK19WT and especially STK19D89N strongly enhanced 
signaling downstream from NRAS (Figure S4E). These results confirm that STK19, and particularly the 
STK19D89N mutant, promotes oncogenic NRAS-driven melanomagenesis in vivo.  
 
Development of ZT-012-037-1 (1a) as a specific small molecule STK19 inhibitor  
Given the pivotal role of NRAS signaling in melanomagenesis and the prominent role of STK19 in NRAS 
activation, targeting STK19 would represent a potential new therapeutic strategy in melanoma, especially 
in those with NRAS mutations. Therefore, to identify pharmacological inhibitors of STK19 kinase activity, 
we screened an in-house library of small molecule compounds based on an optimized biochemical ADP 
generation assay using recombinant purified human STK19 and NRASQ61R proteins (Figure S5A). The 
optimal kinase reaction conditions were chosen through multiple rounds of optimization and validation 
(Figures S5B and S5C). MP-IN-317, also known as UNC0642, a selective G9a and GLP histone lysine 
methyltransferase inhibitor (Liu et al., 2013), was initially identified as the best hit. We then performed 
structure-activity relationship (SAR) studies to improve the selectivity and reduce off-target effects 
towards STK19. After iterative rounds of medicinal chemistry optimization, ZT-12-037-01 (1a) was 
obtained (Figure 5A) with similar potent inhibitory activity against STK19 compared to MP-IN-317 with 
an IC50 of 24.04 nM and 30.45 nM respectively (Figure 5B), but remarkably decreased inhibitory activity 
towards the G9a histone lysine methyltransferase with an IC50 of 467.4 nM and 7.01 nM (Figure S5D). 
On the other hand, another G9a/GLP specific inhibitor A-366 with different chemical scaffold (Sweis et 
al., 2014), showed little inhibitory potential toward STK19 (Figure S5E). Additionally, 1a was 
determined to have extremely high kinase selectivity using KINOMEscan (Table S1), which profiled the 
inhibitor at a concentration of 1 µM against a panel of 468 diverse kinases using an in vitro ATP-site 
competition binding assay (Karaman et al., 2008). 1a was therefore picked to be further validated for 
STK19-targeted inhibition and experimental therapy in melanoma.  
   ZT-12-037-01 (1a) treatment efficiently inhibited phosphorylation of NRAS in a dose- and time- 
dependent manner (Figures 5C and 5D). Furthermore, with increasing ATP concentrations, the IC50 of 
1a against STK19 accordingly increased (Figure 5E), indicating that 1a is an ATP-competitive inhibitor 
for STK19. 1a also showed a high-affinity interaction with STK19 protein, as demonstrated by a shift of 
6.8 °C in the melting temperature of STK19 (Figure 5F). To develop inhibitor-resistant alleles of STK19 
that compromise the inhibitor binding, we performed a series of mutagenesis and biochemical studies 
based on the functional motifs and the hinge region (R131 to V150) within STK19. Introduction of single 
mutation of valine 134 to tyrosine (V134Y) or lysine 139 to phenylalanine (L139F) had minimal effects 
on STK19 kinase activity, but remarkably compromised the inhibitory potential of 1a for STK19 (Figures 
S5F and S5G). These results demonstrate that 1a is on-target to STK19. We also found that 1a has similar 
IC50 for STK19WT and STK19D89N (23.96 nM and 27.94 nM, respectively) (Figure S5H). The consistent 
inhibitory effects of 1a on STK19WT and STK19D89N-activated NRAS phosphorylation were also detected 
in HPMs (Figure 5G). These data suggest that the inhibitory ability of 1a on STK19 was not dependent 
on a region around D89 within STK19. Importantly, 1a did not affect mouse weight (Figure S5I), serum 
transaminase levels (Table S2) or histology of mouse tissues (Figure S5J), suggesting that ZT-12-037-
01 (1a) is a highly potent STK19 inhibitor with low in vivo toxicity. 
 
ZT-012-037-1 (1a) inhibits oncogenic NRAS-driven melanoma development and growth 
To determine whether ZT-12-037-01 (1a) represented a potential therapeutic option for NRAS mutant 
melanoma, genetically engineered NRASQ61R-expressing human immortal melanocytes 
(hTERT/p53DD/CDK4(R24C)) ectopically expressing STK19WT or STK19D89N (Figure S6A) were 
treated with 1a. We found that 1a treatment significantly inhibited mutant NRAS/STK19-driven 
melanocyte colony formation (Figure 6A), proliferation (Figure S6B) and tumor formation (Figures 6B-
6D). 1a treatment also inhibited growth of SK-MEL-2 xenograft melanoma (with NRASQ61R) in a dose-
dependent manner (Figures 6E-6G). We also performed immunofluorescence on SK-MEL-2 xenograft 
tumors to investigate the effects of 1a on in vivo proliferation and apoptosis, represented by Ki67 and 
cleaved caspase-3 staining. We observed that 1a treatment effectively inhibited cell proliferation and 
induced apoptosis of SK-MEL-2 tumors (Figures 6H and 6I), confirming the in vivo efficacy of 1a. We 
then assessed the effects of 1a on survival rate of SK-MEL-2 xenograft tumor-bearing mice and observed 
that 1a significantly prolonged the survival of recipients compared with controls (Figure S6C). Taken 
together these data indicate the potential therapeutic benefits of targeting STK19 with ZT-12-037-01 (1a) 
in melanomas with mutant NRAS.  
   Next, we determined whether the treatment effects of 1a are mediated by inhibiting NRAS signaling. 
Different doses of 1a (0 μM, 1 μM, or 3 μM) were used to treat STK19-depleted HPMs ectopically 
expressing NRASQ61R that were infected with retroviruses encoding empty Flag, Flag-tagged STK19WT, 
or STK19D89N. We found that 1a effectively inhibited STK19WT- and STK19D89N-induced NRAS 
phosphorylation and activation of its downstream signaling (Figure S6D). We also collected SK-MEL-2 
xenograft tumors with treatment of different doses of 1a for immunoblot analysis to confirm that 1a 
targeted STK19 to inhibit NRAS signaling but not G9a activity. Consistently, 1a inhibited NRAS activity 
in a dose-dependent manner, but did not affect the levels of H3K9 methylation (Figure S6E), a 
downstream marker of G9a activity (Shinkai and Tachibana, 2011). 
   In addition, we investigated the growth inhibitory effects of 1a in melanoma cells with different NRAS 
and BRAF status, including A375 and UACC62 (NRASWT, BRAFV600E), and SK-MEL-2 and WM2032 
(NRASQ61R, BRAFWT).  We found that 1a effectively inhibited NRAS signaling, including the MEK-ERK 
and PI3K pathways in SK-MEL-2 and WM2032 cells (with NRASQ61R), but the inhibition was much less 
effective in A375 or UACC62 cells (with NRASWT) (Figure S6F). Consistently, 1a effectively inhibited 
cell growth (Figure S6G) and induced apoptosis (Figure S6H) of SK-MEL-2 and WM2032 melanoma 
cells, but exhibited a reduced impact on A375 or UACC62 cells. These results indicate that pro-apoptotic 
effect of ZT-12-037-01 (1a) is dramatically enhanced in cells expressing oncogenic NRAS.  
   To confirm the specificity of the targeted inhibition of STK19 by 1a, lower concentrations of 1a (100 
nM and 300 nM) were evaluated in SK-MEL-2 and WM2032 melanoma cells and the levels of H3K9 
methylation and NRAS phosphorylation and activity were investigated by immunoblotting. We found up 
to 300 nM, 1a had no obvious effects on H3K9 methylation but still effectively decreased NRAS 
phosphorylation and activity (Figure S6I). To further confirm the pharmacological effects of 1a derive 
from STK19 inhibition and not G9a inhibition, we investigated the role of G9a in NRAS signaling 
activation. G9a was silenced by G9a-specific shRNA or inhibited by a specific inhibitor, A-366, in SK-
MEL-2 and WM2032 melanoma cells. We observed the inhibition of G9a activity by knockdown (Figure 
S6J) or treatment with A-366 (Figure S6K) markedly repressed H3K9 methylation levels but not NRAS 
signaling, indicating that 1a inhibited NRAS activity via targeting STK19 but not G9a. We also found that 
1a-mediated inhibition of oncogenic NRAS signaling was rescued by introduction of 1a-resistant STK19 
V134Y or L139F, confirming the inhibition specificity of 1a towards STK19 (Figure S6L). In summary, 
ZT-12-037-01 (1a) is a specific STK19-targeted inhibitor to block oncogenic NRAS-driven melanocyte 
malignant transformation and melanoma growth. 
 
DISCUSSION 
The development of targeted cancer therapies is facilitated by understanding the functional consequences 
of genetic driver mutations that lead to overactive signaling pathways. The three RAS genes (KRAS, HRAS 
and NRAS) are frequently activated by mutation in about 25% of all cancers including melanomas, 
pancreatic ductal adenocarcinomas, colorectal adenocarcinomas and lung adenocarcinomas (Cox et al., 
2014; Lee et al., 2011; Stephen et al., 2014). Activating mutations in RAS family members and components 
of the downstream MEK/ERK signaling pathway also account for development of a group of genetic 
syndromes known as RASopathies (Rauen, 2013). However, unlike the downstream effectors of RAS, such 
as BRAF and MEK whose targeted therapy has been extensively exploited through the successful 
development of several small molecule inhibitors (Chapman et al., 2011; Flaherty et al., 2010; Kefford et 
al., 2010; Larkin et al., 2014; Long et al., 2017a, b), little progress has been made towards targeting 
activation of RAS proteins.  
  For example, since the activation of oncogenic RAS depends on the protein’s localization at the inner face 
of plasma membrane for effector binding, efforts have been made towards targeting the hydrophobic 
modifications of the C-terminal HVR domain necessary for RAS plasma membrane association (Ahearn et 
al., 2011; Barcelo et al., 2013; Berndt et al., 2011; Buss and Sefton, 1986; Casey et al., 1989; Wright and 
Philips, 2006). Moreover, the observation that RAS proteins are prenylated for plasma membrane 
localization and activation initially led to the development of farnesyltransferase inhibitors (FTIs) aimed at 
preventing RAS localization to the plasma membrane (Brunner et al., 2003). However, these attempts were 
unsuccessful in clinical trials because RAS proteins are also modified by geranylgeranyl isoprenoid to retain 
their membrane association (Karnoub and Weinberg, 2008). It has also recently been reported that a small 
molecule RAS-mimetic rigosertib and pan-RAS ligands block RAS binding to effector proteins, bringing 
new possibilities for anti-RAS therapy (Athuluri-Divakar et al., 2016; Welsch et al., 2017). In addition to 
these strategies, others have also considered targeting kinases/phosphatases that regulate RAS activity. 
Phosphorylation of NRAS at Y32 by the kinase SRC, which was recognized as a proto-oncogene protein to 
activate RAS and MEK/ERK signaling, was reported to inhibit RAS activity through GTP hydrolysis and 
dissociation of RAF binding (Bunda et al., 2014). Consequently, inhibition of SHP2 which mediates RAS 
dephosphorylation can suppress tumor growth in multiple cancers (Bunda et al., 2015; Mainardi et al., 2018; 
Wong et al., 2018). However, it remains to be seen whether these recent observations will be successfully 
translated to the clinic as therapies for cancers bearing oncogenic RAS. 
   In this study, rather than targeting RAS directly we identified and characterized the poorly studied 
serine/threonine kinase STK19 as a novel activator of NRAS. Our observations suggest that for activated 
NRAS to signal effectively and exert its oncogenic effects on melanocytes it needs to be phosphorylated on 
the S89 by STK19. Phosphorylation at S89 then promotes NRAS interaction with its downstream effector 
and accordingly STK19 activates NRAS signaling via the MEK/ERK and PI3K pathways. The identification 
of STK19 as a critical kinase upstream from NRAS prompted us to hypothesize that STK19 would represent 
a therapeutic vulnerability in NRAS-driven melanomas. Consistent with this, the selective STK19 inhibitor 
ZT-12-037-01 (1a) developed here exhibits impressive inhibitory effects on STK19-induced NRAS 
phosphorylation and NRAS-driven melanoma progression in vitro and in vivo. Our results therefore offer a 
preclinical proof of concept for therapeutic targeting of the STK19 kinase in melanomas with NRAS 
mutations.  Significantly, although we have focused on NRAS, we note that S89, the key residue in NRAS 
phosphorylated by STK19, is conserved in all the three RAS proteins. Since depletion or inhibition of 
STK19 limits the transforming potential of oncogenic NRAS in melanocytes and inhibits growth of NRAS 
mutant melanoma, our results suggest that targeting STK19 may represent a promising therapeutic approach 
for anti-RAS therapies in general.  
   Many different genetic driver mutations have been identified in melanomagenesis, most notably those 
affecting BRAF, NRAS, INK4a, PTEN and p14ARF (Fargnoli et al., 2008; Kim et al., 2008; Landi et al., 
2006; Scherer et al.; Tsao et al., 2012). Our knowledge of driver genes in melanoma has recently been 
augmented by large-scale massively parallel sequencing studies that have identified additional 
significantly mutated genes include NF1, ARID2, PPP6C, SNX31, TACC1, STK19, and RAC1 from the 
initial large-scale melanoma exome data (Hodis et al., 2012; Krauthammer et al., 2012), as well as 
MAP2K1, IDH1, RB1, and DDX3X in the Cancer Genome Atlas Skin Cutaneous Melanoma (SKCM-
TCGA) exome sequencing dataset (Akbani et al., 2015). Here our cellular and genetic studies extended 
these observations to identify the STK19D89N mutant as a gain-of-function mutation in melanomas which 
accelerates oncogenic NRAS-driven melanomagenesis in vivo. We also found that overexpression and 
mutations of STK19 were detected in about 25% of human melanomas and that higher STK19 expression 
conferred a substantially increased risk of mortality in patients with primary melanomas. However, no 
melanoma was observed in mice with an STK19D89N knockin alone. Our data therefore suggest that the 
STK19 mutant is not a typical driver, but is perhaps a helper mutation that facilitates melanoma 
development by activation of NRAS signaling. Notably, unlike those mutations activating NRAS 
(Q61R/L/K) or BRAF (V600E), the significant hotspot D89N in STK19 corresponds to cytosine to a 
thymidine (C>T transition) UVR signature mutation in melanoma (Brash, 2015). As such our results may 
go some way to explain the association of NRAS mutation-associated melanoma with UVR if STK19 
accelerates UVR-driven melanomagenesis in individuals with NRAS mutations.  
   Targeted therapies have significantly improved clinical outcomes in patients with various cancers such 
as BRAF inhibitors for metastatic melanoma and epidermal growth factor receptor (EGFR) inhibitors for 
EGFR mutant non-small cell lung cancer (NSCLC) (Chapman et al., 2011; Siegelin and Borczuk, 2014). 
However, the efficacy is almost always ultimately compromised by the acquisition of drug resistance, 
which frequently involves RAS mutations or reactivation of the MEK/ERK and PI3K pathways (Ercan et 
al., 2012; Hatzivassiliou et al., 2010). The ability to target RAS signaling using the STK19 inhibitor ZT-
12-037-01 (1a) developed here might be further evaluated for rational integration of combination therapy 
to overcome or prevent drug-resistance in patients with RAS mutation cancers in future preclinical and 
ultimately clinical studies.  
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FIGURE LEGENDS 
Figure 1. STK19 is a critical regulator of NRAS function. 
A. Strategy used for identification of kinases regulating NRASQ61R-effector protein:protein interaction. 
B. Whole-kinome screen identifies STK19 as a novel regulator of NRASQ61R activity. Active NRAS 
chemiluminescence assay was performed to screen a total of 709 kinases whose knockdown affects 
interaction between NRASQ61R and GST-CRAF RBD fusion protein. Vertical axis represents relative level 
of active NRAS compared to group treated with control siRNA. Data are means of three individual kinase-
targeting siRNA. 
C. STK19 alterations were identified in 25.07% of 363 melanoma cases (TCGA, PanCancer Atlas). 
D. STK19 was depleted in human primary melanocytes infected with retroviruses encoding empty HA, 
HA-NRASWT, or HA-NRASQ61R. Active HA-NRAS proteins were pulled down by GST-CRAF RBD 
fusion protein. Active HA-NRAS levels and activation of NRAS downstream signaling were detected by 
immunoblots. shCTRL, non-targeting shRNA. shSTK19, shRNA targeting STK19. 
E. hTERT/p53DD/CDK4(R24C) melanocytes expressing empty HA, HA-NRASWT or HA-NRASQ61R 
were introduced with control shRNA or STK19 shRNA, and then seeded for colony formation assay. Data 
are means ± SD relative to control group with control shRNA and empty HA (n=6).  
F-H. Growth curve, tumor weight, and dissected tumors for the xenograft experiments with indicated cells 
inoculated subcutaneously into flanks of nude mice. Visible tumors were measured every three days. Data 
are means ± SEM relative to control group (n=6). 
See also Figure S1. 
 
Figure 2. STK19 phosphorylates NRAS protein at serine 89. 
A. Mass spectral peptide count of STK19-interacting proteins. 
B-C. Exogenous interactions between HA-NRAS and STK19-Flag were detected by immunoprecipitation 
in HPMs with overexpression of STK19-Flag and empty HA, HA-NRASWT or HA-NRASQ61R. 
D. HPMs were introduced with retroviruses encoding empty HA, HA-NRASWT or HA-NRASQ61R and/or 
STK19-Flag. The serine-, threonine- and tyrosine-phosphorylation of HA-NRAS isoforms were detected 
by immunoblots with specific antibodies. 
E. Mass spectrometry analysis to identify serine 89 (S89) as the phosphorylation residue by STK19. 
F. Schematic diagram showing the evolutionarily conserved serine residue (S89) in NRAS. 
G. An in vitro kinase assay was performed using purified recombinant human STK19 protein and indicated 
purified recombinant human NRAS isoform proteins, followed by detection of phosphorylation in NRAS. 
H. HPMs were introduced with empty HA, HA-NRASWT, HA-NRASS89A, HA-NRASQ61R, or HA-
NRASQ61R/S89A. The NRAS-effector protein:protein interaction (including BRAF, CRAF and PI3Kα), 
active HA-NRAS levels and activation of NRAS downstream signaling were detected by immunoblots 
after infection with retroviruses encoding empty Flag or Flag-tagged STK19. 
I. hTERT/p53DD/CDK4(R24C) melanocytes expressing empty HA, HA-NRASQ61R or HA-
NRASQ61R/S89A were introduced with retroviruses encoding empty Flag or Flag-tagged STK19, and then 
seeded for colony formation assay. Data are means ± SD relative to control group with empty HA vector 
and empty Flag vector (n=6). 
J-L. Growth curve, tumor weight, and dissected tumors for the xenograft experiments with indicated cells 
inoculated subcutaneously into flanks of nude mice. Visible tumors were measured every three days. Data 
are means ± SEM relative to control group (n=7). 
See also Figures S2. 
 
Figure 3. STK19 D89N is a recurrent gain-of-function mutation. 
A. STK19 mutations in TCGA database. 
B. An in vitro kinase assay was performed using purified recombinant human STK19WT and STK19D89N 
proteins and indicated human NRAS isoform proteins, followed by detection of phosphorylation in NRAS. 
C. HPMs with depletion of STK19 and overexpression of empty HA, HA-NRASWT, or HA-NRASQ61R 
were further infected with retroviruses encoding empty Flag, Flag-tagged STK19WT or STK19D89N. Serine 
phosphorylation of HA-NRAS, active HA-NRAS levels and activation of NRAS downstream signaling 
were detected by immunoblots. 
D. hTERT/p53DD/CDK4(R24C) melanocytes expressing STK19 shRNA and empty HA, HA-NRASWT 
or HA-NRASQ61R were introduced with retroviruses encoding empty Flag, Flag-tagged STK19WT or 
STK19D89N, and then seeded for colony formation assay. Data are means ± SD relative to control group 
with empty HA vector and empty Flag vector (n=6). 
E-G. Growth curve, tumor weight, and dissected tumors for the xenograft experiments with indicated cells 
inoculated subcutaneously into flanks of nude mice. Visible tumors were measured every three days. Data 
are means ± SEM relative to control group (n=6). 
See also Figure S3. 
 
Figure 4. STK19 D89N induces melanomagenesis in the presence of oncogenic NRAS in vivo.  
A. Tyr-Cre, Tyr-Cre-STK19WT and Tyr-Cre-STK19D89N knockin mice. 
B. Ears of Tyr-Cre, Tyr-Cre-STK19WT and Tyr-Cre-STK19D89N knockin mice. 
C. Tails of Tyr-Cre, Tyr-Cre-STK19WT and Tyr-Cre-STK19D89N knockin mice. 
D. Fontana Masson staining of indicated mouse ears. 
E. Quantification of skin melanin content in Tyr-Cre, Tyr-Cre-STK19WT and Tyr-Cre-STK19D89N knockin 
mice. Data are means ± SD relative to Tyr-Cre control group (n=3).  
F. Primary mouse melanocytes derived from indicated mice were lysed for immunoblot analysis of human 
STK19 expression and NRAS signaling pathways after treatment of 4-hydroxytamoxifen (4-OHT). 
G. Melanoma-free survival. Tyr-Cre, n=20; Tyr-Cre-NRASQ61R, n=18; Tyr-Cre-STK19WT, n=19; Tyr-
Cre-STK19D89N, n=20; Tyr-Cre-NRASQ61R-STK19WT, n=19; Tyr-Cre-NRASQ61R-STK19D89N, n=19. By 
log-rank test, P=0.0116 (Tyr-Cre-NRASQ61R, Tyr-Cre-NRASQ61R-STK19WT), P<0.001 (Tyr-Cre-
NRASQ61R, Tyr-Cre-NRASQ61R-STK19D89N), P=0.0269 (Tyr-Cre-NRASQ61R-STK19WT, Tyr-Cre-NRAS 
Q61R-STK19D89N). 
See also Figure S4. 
 
Figure 5. Development of ZT-012-037-1 (1a) as a specific small molecule STK19 inhibitor. 
A. The chemical structure of ZT-012-037-1 (1a). 
B. The inhibitory activity of MP-IN-317 and 1a for STK19, measured as percentage of NRAS 
phosphorylation. Data are means ± SD relative to control group (n = 3). IC50 represents median inhibitory 
concentration. 
C-D. Phosphorylation of HA-NRASQ61R was detected by immunoblots with an in vitro kinase assay at 
different doses of 1a for 15 min or 3 µM of ZT-012-037-1 for different reaction time. 
E. IC50 values of 1a against STK19 at different ATP concentrations. Data are means ± SD relative to 
control groups (n = 3).  
F. The thermal denaturation curve shift of STK19 (10 µM) in the presence of 1a (100 µM).  
G. Immunoblots to detect inhibition of STK19WT and STK19D89N by 1a at different concentrations. 
See also Figure S5, Tables S1 and S2. 
 
Figure 6. ZT-012-037-1 (1a) inhibits oncogenic NRAS-driven melanoma development and growth. 
A. hTERT/p53DD/CDK4(R24C) melanocytes induced with STK19 shRNA and retroviruses encoding 
empty Flag, Flag-tagged STK19WT or STK19D89N were treated with 3 μM 1a or not, and proceeded for 
colony formation assay. Data are means ± SD relative to control group (n=6).  
B-D. Growth curve, tumor weight, and dissected tumors for the xenograft experiments with indicated cells 
inoculated subcutaneously into flanks of nude mice treated with 1a. Visible tumors were measured every 
three days. Data are means ± SEM relative to control group (n=6). 
E-G. Growth curve, tumor weight, and dissected tumors for the xenograft experiments with SK-MEL-2 
cells inoculated subcutaneously into flanks of nude mice treated with 1a.  Visible tumors were measured 
every three days. Data are means ± SEM relative to control group (n=7). 
H-I. Effects of 1a treatment on in vivo proliferation and apoptosis were evaluated by staining of the 
sections of tumor collected in G for Ki67 and cleaved caspase-3. The sections were counterstained with 
DAPI. Data are means ± SD (n=7). Representative images were shown. Scale bar, 100 µm.  
See also Figures S6. 
 
SUPPLEMENTAL FIGURE LEGENDS 
Figure S1. STK19 is a critical regulator of NRAS function, related to Figure 1. 
A. Mutual exclusivity between STK19 and BRAF alterations in TCGA PanCancer Atlas. 
B. STK19 was depleted in A375, UACC62, SK-MEL-2 and WM2032 cells. Active NRAS proteins were 
pulled down by GST-CRAF RBD fusion protein. Active NRAS levels and activation of NRAS 
downstream signaling were detected by immunoblots. 
C. STK19 was depleted in HPM, A375, UACC62, SK-MEL-2 and WM2032 cells, and the cell 
proliferation rates were measured.  Data are means ± SD relative to individual control group (n=6). 
D. qRT-PCR analysis of STK19 mRNA levels in SK-MEL-2 and WM2032 cells infected with STK19 
shRNAs. Error bars indicate 95% confidence interval of triplicates. 
E. STK19 was depleted in SK-MEL-2 and WM2032 cells. Active NRAS proteins were pulled down by 
GST-CRAF RBD fusion protein. Active NRAS levels and activation of NRAS downstream signaling 
were detected by immunoblots. 
F. SK-MEL-2 and WM2032 cells with depletion of STK19 were infected with retroviruses encoding 
empty Flag or Flag-tagged STK19WT. Active NRAS proteins were pulled down by GST-CRAF RBD 
fusion protein. Active NRAS levels and activation of NRAS downstream signaling were detected by 
immunoblots. 
G. Immunoblots to show depletion of STK19 and overexpression of HA-NRAS proteins in 
hTERT/p53DD/CDK4(R24C) melanocytes. 
H. hTERT/p53DD/CDK4(R24C) melanocytes expressing empty HA, HA-NRASWT or HA-NRASQ61R 
were introduced with control shRNA or STK19 shRNA, and then seeded for cell proliferation assay. Data 
are means ± SD relative to control group (n=6). 
 
Figure S2. STK19 phosphorylates NRAS protein at serine 89, related to Figure 2. 
A. Strategy to identify STK19-interacting proteins by mass spectrometry analysis. 
B-C. Endogenous STK19-NRAS interactions were detected by immunoprecipitation in SK-MEL-2, 
WM2032, A375 and UACC62 cells. 
D. The serine phosphorylation of NRAS in a panel of melanoma cells was detected by immunoblots. 
E. STK19 was depleted by shSTK19 in HPMs overexpressing empty HA, HA-NRASWT, or HA-
NRASQ61R. The serine phosphorylation of HA-NRAS was detected by immunoblots. 
F. The serine phosphorylation of NRAS was detected by immunoblots in SK-MEL-2 and WM2032 cells 
with depletion of endogenous STK19. 
G. HPMs with depletion of STK19 and overexpression of HA-tagged empty vector, HA-NRASWT, or HA-
NRASQ61R were further infected with retroviruses encoding Flag tagged empty vector, Flag-tagged 
STK19WT or kinase-dead STK19K317P. The serine phosphorylation of HA-NRAS and STK19-NRAS 
interactions were detected by immunoblots. 
H. The serine phosphorylation of NRAS was detected by immunoblots in SK-MEL-2 and WM2032 cells 
with depletion of endogenous STK19 and overexpression of empty Flag, Flag-tagged STK19WT or kinase 
dead STK19K317P. 
I. An in vitro kinase assay was performed using purified recombinant human STK19 protein and human 
NRAS (WT and Q61R) protein followed by detection of phosphorylation in NRAS. 
J. Purified recombinant human NRAS protein preloaded with GDP, GTP or GTPγS were incubated with 
purified recombinant human STK19 protein for in vitro kinase assay followed by detection of 
phosphorylation in NRAS. 
K. HPMs were transduced with indicated NRAS mutant isoforms and Flag-tagged STK19. The serine 
phosphorylation of HA-NRAS and STK19-NRAS interactions were detected by immunoblots. 
L. HPMs were transduced with empty HA, HA-NRASWT, HA-NRASS89D, HA-NRASQ61R, or HA-
NRASQ61R/S89D. The NRAS-effector protein:protein interaction (including BRAF, CRAF and PI3Kα), 
active HA-NRAS levels and activation of NRAS downstream signaling were detected by immunoblots. 
M. Immunoblots to show overexpression of HA-NRAS and STK19-Flag isoforms in 
hTERT/p53DD/CDK4(R24C) melanocytes. 
N. hTERT/p53DD/CDK4(R24C) melanocytes expressing empty HA, HA-NRASWT, HA-NRASS89A, HA-
NRASQ61R or HA-NRASQ61R/S89A were introduced with retroviruses encoding empty Flag or Flag-tagged 
STK19, and then seeded for cell proliferation assay.  Data are means ± SD relative to control group (n=6). 
O. Immunoblots to show overexpression of HA-NRAS isoforms in hTERT/p53DD/CDK4(R24C) 
melanocytes. 
P. hTERT/p53DD/CDK4(R24C) melanocytes were transduced with retroviruses encoding empty HA, 
HA-NRASWT, HA-NRASS89D, HA-NRASQ61R or HA-NRASQ61R/S89D, and then seeded for colony 
formation assay. Data are means ± SD relative to control group with empty HA vector (n=6). 
Q. hTERT/p53DD/CDK4(R24C) melanocytes were transduced with retroviruses encoding empty HA, 
HA-NRASWT, HA-NRASS89D, HA-NRASQ61R or HA-NRASQ61R/S89D, and then seeded for cell 
proliferation assay. Data are means ± SD relative to control group with empty HA vector (n=6). 
R-T. Growth curve, tumor weight, and dissected tumors for the xenograft experiments with indicated cells 
inoculated subcutaneously into flanks of nude mice. Visible tumors were measured every three days. Data 
are means ± SEM relative to control group (n=7). 
 
Figure S3. STK19 D89N is a recurrent gain-of-function mutation, related to Figure 3. 
A-B. SK-MEL-2 and WM2032 cells were treated with indicated conditions, and active NRAS levels and 
activation of NRAS downstream signaling in the melanoma cells were detected by immunoblots. 
C. SK-MEL-2 and WM2032 cells were treated with indicated conditions, and the cell proliferation rates 
were measured.  Data are means ± SD relative to individual control group (n=6). 
D. Immunoblots to show overexpression of HA-NRAS and STK19-Flag isoforms in 
hTERT/p53DD/CDK4(R24C) melanocytes. 
E. hTERT/p53DD/CDK4(R24C) melanocytes expressing STK19 shRNA and empty HA, HA-NRASWT 
or HA-NRASQ61R were introduced with retroviruses encoding empty Flag, Flag-tagged STK19WT or 
STK19D89N, and then seeded for cell proliferation assay. Data are means ± SD relative to control group 
(n=6). 
 
Figure S4. STK19 D89N induces melanomagenesis in the presence of oncogenic NRAS in vivo, 
related to Figure 4.  
A. Schematic representation to generate the conditional knockin C57BL/6 mice with human STK19WT or 
STK19D89N. 
B. PCR was performed to select mice with expression of STK19WT or STK19D89N in indicated mouse 
strains. 
C. Immunoblots to confirm the expression of STK19WT or STK19D89N protein in indicated mouse strains. 
D. Schematic representation to observe melanoma development. 
E. Melanoma tissues from Tyr-Cre-NRASQ61R, Tyr-Cre-NRASQ61R-STK19WT and Tyr-Cre-NRASQ61R-
STK19D89N knockin mice were collected for immunoblotting. Active NRAS proteins were pulled down 
by GST-CRAF RBD fusion protein. Active NRAS levels and activation of NRAS downstream signaling 
were detected by immunoblots. 
 
Figure S5. Development of ZT-012-037-1 (1a) as a specific small molecule STK19 inhibitor, related 
to Figure 5. 
A. Schematic representation of the in vitro STK19 kinase activity assay using HA-NRASQ61R as the 
substrate. 
B. The kinase assays were performed using gradient concentrations of STK19-Flag for the indicated 
reaction time with 100 µM ATP concentration to establish the optimal STK19 concentration (12.5 nM) 
and reaction time (15 min). Data are means ± SD (n = 3).  
C. Gradient concentrations of ATP (0.5 µM to 200 µM) were incubated with 12.5 nM STK19-Flag for 15 
min for the STK19 kinase activity assay. ATP Km (app) was calculated by fitting the data with Michaelis-
Menten equation. Data are means ± SD (n = 3). 
D. IC50 of MP-IN-317 and ZT-012-037-1 (1a) for inhibition of G9a enzyme activity with in vitro 
methyltransferase assay. Data are means ± SD relative to control group (n=3). 
E. Relative inhibition of STK19 enzyme by ZT-012-037-1 (1a) and A-366 was calculated following in 
vitro kinase assay. Data are means ± SD relative to control group (n=3). 
F. IC50 values for the inhibition of STK19 WT or mutants STK19 V134Y and L139F by 1a. Data are 
means ± SD relative to control groups (n = 3).  
G. Phosphorylation of HA-NRasQ61R was detected by immunoblots in HPMs with knockdown of STK19 
and overexpression of HA-NRasQ61R and indicated STK19 isoforms.  
H. IC50 values for the inhibition of STK19WT or STK19D89N by 1a. Data are means ± SD relative to control 
groups (n = 3).  
I. Body weight measurements of C57BL/6J mice treated with 0 or 25 mg/kg 1a (BID) for 15 days. Data 
are means ± SEM relative to control groups (n = 8).  
J. H&E staining of tissues in C57BL/6J mice treated with 0 or 25 mg/kg 1a (BID) for 15 days. Scale bar, 
250 µm. 
 
Figure S6. ZT-012-037-1 (1a) inhibits oncogenic NRAS-driven melanoma development and growth, 
related to Figure 6. 
A. Immunoblots to show overexpression of HA-NRAS and STK19-Flag isoforms in 
hTERT/p53DD/CDK4(R24C)-shSTK19 melanocytes. 
B. hTERT/p53DD/CDK4(R24C) melanocytes infected with STK19 shRNA and retroviruses encoding 
empty Flag, Flag-tagged STK19WT or STK19D89N were treated with 1a (3 μM) or not, and then seeded for 
cell proliferation assay. Data are means ± SD relative to control group (n=6). 
C. Survival evaluation of SK-MEL-2 xenograft-bearing mice treated with 1a. By log-rank test, P<0.001 
(control, 25 mg/kg 1a); P<0.001 (control, 50 mg/kg 1a). 
D. HPMs with depletion of STK19 and overexpression of HA-NRASQ61R were transduced with 
retroviruses encoding empty Flag, Flag-tagged STK19WT or STK19D89N, and then treated with indicated 
concentrations of 1a. Serine phosphorylation of NRASQ61R, active HA-NRAS levels and activation of 
NRAS downstream signaling were detected by immunoblots. 
E. SK-MEL-2 xenograft tumors from Figure 6G were collected. Serine phosphorylation of NRASQ61R, 
active NRAS levels, activation of NRAS downstream signaling and H3K9 methylation were detected by 
immunoblots. 
F. A375, UACC62, SK-MEL-2 and WM2032 cells were treated with indicated concentrations of 1a. 
Serine phosphorylation of NRAS, active NRAS levels and activation of NRAS downstream signaling in 
these melanoma cells were detected by immunoblots. 
G. A375, UACC62, SK-MEL-2 and WM2032 cells were treated with indicated concentrations of 1a for 
4 days, and the cell proliferation rates were measured.  Data are means ± SD relative to individual control 
group (n=6). 
H. A375, UACC62, SK-MEL-2 and WM2032 cells were treated with indicated concentrations of 1a for 
4 days, and the caspase activity assays were performed to investigate apoptosis.  Data are means ± SD 
relative to individual control group (n=6). 
I. SK-MEL-2 and WM2032 cells were treated with indicated low concentrations of 1a. Serine 
phosphorylation of NRAS, activation of NRAS signaling and H3K9 methylation in these melanoma cells 
were detected by immunoblots. 
J. G9a was depleted in SK-MEL-2 and WM2032 cells. Active NRAS proteins were pulled down by GST-
CRAF RBD fusion protein. Active NRAS levels, activation of NRAS downstream signaling and H3K9 
methylation were detected by immunoblots. 
K. SK-MEL-2 cells were treated with indicated concentrations of 1a or A-366. Serine phosphorylation of 
NRAS, active NRAS levels, activation of NRAS downstream signaling and H3K9 methylation were 
detected by immunoblots. 
L. SK-MEL-2 cells were infected with retroviruses encoding empty Flag, Flag-tagged STK19WT or STK19 
mutants, and then treated with 1a or not. Serine phosphorylation of NRAS, active NRAS levels, activation 
of NRAS downstream signaling and H3K9 methylation were detected by immunoblots. 
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CONTACT FOR REAGENT AND RESOURCE SHARING 
Further information and requests for resources and reagents should be directed to and will be fulfilled by 
the Lead Contact, Rutao Cui (rutaocui@bu.edu). 
 
EXPERIMENTAL MODEL AND SUBJECT DETAILS 
Animal procedures 
The generation of Rosa26-knock-in STK19WT and STK19D89N C57BL/6 mice using CRISPR/Cas9 
technology was described previously (Chu et al., 2016). cDNA of human STK19WT or STK19D89N was 
inserted into the vector pR26 CAG (Addgene, #74286) via restriction enzymes AsiSI (NEB, R0630) and 
MluI (NEB, R3198), respectively. The generated STK19-coding construct, together with sgRosa26-1 (5’-
ACTCCAGTCTTTCTAGAAGA) targeting Rosa26 intronic XbaI site and Cas9 mRNA in vitro 
transcribed from pCAG-Cas9-162A (Addgene, #84918), were microinjected into the pronuclei of 
C57BL/6 zygotes. The injected zygotes were transferred into the oviducts of pseudo-pregnant NMRI 
female mice to obtain live pups. Microinjection and zygote injection were performed in MIT Transgenic 
Core. At 21 days of age, genomic DNA was extracted from the mouse tail biopsy for genotyping to 
examine the correct insertion of STK19WT and STK19D89N cDNA. The STK19 knock-in mice were further 
crossed with Tyr-Cre mice (purchased from Jackson Lab and originally generated by Dr. Marcus 
Bosenberg (Dankort et al., 2009)) and loxP/STOP/loxP NRASQ61R knockin (LSL-NRASQ61R) mice (kind 
gifts from Drs. Norman Sharpless and David Fisher) to generate indicated mice for experiments. All mice 
were maintained in a specific-pathogen-free facility of the Animal Science Center (ASC) of Boston 
University Medical Campus, and the experiments were performed according to the Institutional Animal 
Care and Use Committee of Boston University Medical Campus. Mice were housed on a time cycle of 12 
h of light (beginning at 6:00) and 12 h of dark (beginning at 18:00). Mice were allowed free access to an 
irradiated diet and sterilized water. The mice were monitored daily for signs of health status and distress. 
   For the toxicity profile of 1a inhibitor in C57BL/6J mice, vehicle [5% (w/v) Kolliphor HS 15 (Sigma)] 
in normal saline or 25 mg/kg of 1a formulated in the vehicle was injected twice a day (BID). Mouse body 
weights were measured every day. After indicated days, mice were euthanized. The serum was acquired 
for blood biochemistry analyses using assay kits according to manufacturer’s instructions (Shenzhen 
Mindray Bio-Medical Electronics Co., Ltd.). The organs were separated and processed for H&E staining. 
Specifically, tissues were fixed in 4% paraformaldehyde and embedded in paraffin. Then, 4 μm thick 
slices were stained with haematoxylin and eosin and examined by light microscopy (Leica DM4 M). 
  For in vivo tumorigenesis assay, 2 × 106 hTERT/p53DD/CDK4(R24C) melanocytes or SK-MEL-2 
melanoma cells mixed with matrigel (1:1) were injected subcutaneously into the flanks of 8-week female 
nude mice. Tumor size was measured every 3 days with a caliper, and the tumor volume was determined 
with the formula: Length × Width2 × 0.5. To investigate the inhibitory effects of ZT-12-037-1 (1a) on 
melanomagenesis, 25 mg/kg 1a was intraperitoneally injected once a day. For SK-MEL-2 tumors, 25 
mg/kg 1a was intraperitoneally injected once or twice a day (25 or 50 mg/kg/day) after the tumors have 
grown to 100-200 mm3. The mice were euthanized after indicated days or when the allowable endpoint 
size (1 cm3) was reached. None of the xenograft tumors reached the maximal tumor volume permitted by 
the IACUC of Boston University Medical Campus. The xenograft tumors were dissected and their weights 
were measured. 
Primary melanocytes and cell culture 
Human primary melanocytes (HPMs) were isolated from normal discarded foreskins as described before 
(Chen et al., 2017) and were cultured in Medium 254 (Thermo Fisher Scientific) supplemented with 
Human Melanocyte Growth Supplement (HMGS, Thermo Fisher Scientific, S-002-5). Immortal human 
melanocytes (hTERT/p53DD/CDK4(R24C)) (Garraway et al., 2005) were cultured in glutamine 
containing Ham’s F12 media supplemented with 7% fetal bovine serum (FBS), 0.1 mM IBMX, 50 ng/mL 
TPA, 1 μM Na3VO4, and 1 μM dibutyryl cAMP. All melanoma cell lines are mycoplasma-negative and 
maintained in Dulbecco’s Modified Eagle’s Medium (DMEM) containing 10% fetal bovine serum (FBS), 
100 units of penicillin and 100 mg/mL streptomycin.  
 
METHOD DETAILS 
Plasmids and shRNAs 
The Flag-tagged wild-type STK19 encoding plasmid was purchased from Origene (RC219373L3). The 
HA-tagged wild-type NRAS encoding plasmid pCGN NRAS wt was purchased from Addgene (14723). 
To generate the STK19 or NRAS expression plasmids for retroviral infection, the cDNA were subcloned 
into pQCXIP (Clonetech) at the NotI/EcoRI sites, respectively. All other mutants were generated by site-
directed mutagenesis using QuikChange II Site-Directed Mutagenesis Kit (Agilent) according to the 
manufacture’s instruction. To overexpress wild-type STK19 or NRAS and their mutants, HEK293FT cells 
were co-transfected with pQCXIP-STK19 or pQCXIP-NRAS, pCMV-VSV-G (Addgene, 8454) and 
pUMVC (Addgene, 8449) using Lipofectamine 3000 (Thermal Fisher Scientific) as described previously 
(Chen et al., 2017). Retroviruses were collected 48 h after the transfection, and infected cells for 24 h in 
the presence of 8 μg/mL polybrene. The infected cells were then selected by 2 μg/mL puromycine. To 
knockdown STK19 in melanocytes and melanoma cells, human specific short hairpin RNAs in pLKO.1 
targeting STK19 were co-transfected with psPAX2 (Addgene, 12260) and pMD2.G (Addgene, 12259) 
into HEK293FT cells using Lipofectamine 3000. Lentiviruses were harvested 48 h after the transfection, 
and infected cells for 24 h in the presence of 8 μg/mL polybrene. The infected cells were then selected by 
2 μg/mL puromycine.  
High-throughput siRNA screening of NRAS regulators 
The SilencerTM Human Kinase siRNA Library (Thermo Fisher Scientific) contains 2,127 siRNA targeting 
709 human kinase genes (3 siRNA pooled per gene) supplied in 96-well plates. HEK293FT cells infected 
with recombinant lentiviruses encoding HA-tagged NRASQ61R were transfected with each kinase siRNA 
from the library (final concentration at 20 nM) using Lipofectamine 3000 (Thermo Fisher Scientific) 
according to the manufacturer's instructions. At 48 h after transfection, whole cell lysates from HEK293FT 
cells were collected for RAS activity assay using modified RAS GTPase ELISA Kit (Abcam). Specifically, 
active RAS proteins were captured by GST-CRAF-RBD fusion protein in glutathione-coated plates. The 
bound HA-NRASQ61R was incubated with a horseradish peroxidase (HRP)-conjugated antibody against 
HA tag (Abcam) at room temperature for 30 min. The PierceTM ECL Western Blotting Substrate (Thermo 
Fisher Scientific) was added to generate a sensitive chemiluminescence readout. The levels of RBD-bound 
HA-NRASQ61R after silencing each kinase individually were quantified in relation to control siRNA.  
Quantitative real-time PCR (qRT-PCR) 
Total RNA was extracted with Qiagen RNeasy kit (Invitrogen). cDNA was synthesized using 
SuperScript II Reverse Transcriptase (Invitrogen), and 40 ng cDNA was used for quantitative real-time 
PCR amplification with TaqManTM Gene Expression Master Mix (Thermo Fisher Scientific). The 
relative levels of STK19 expression were normalized according to those of GAPDH. qRT-PCR data 
were calculated using the comparative CT method. All quantitative PCR were performed in triplicates.  
Immunoblot analysis 
Whole cell lysates were prepared using lysis buffer containing 50 mM Tris pH 7.4, 1% Triton X-100, 
0.5 mM EDTA, 0.5 mM EGTA, 150 mM NaCl, 10% glycerol, 1 mM phenylmethylsulfonyl fluoride and 
complete protease inhibitor cocktail (Roche), homogenized and centrifuged at 14,000 rpm for 15 min at 
4 °C.  Protein concentration of cell lysates was determined by Pierce BCA Protein Assay Kit (Thermo 
Fisher Scientific). Cell lysates were incubated in PierceTM Lane Marker Reducing Sample Buffer for 5 
min at 100 °C, separated by 8-12% SDS-PAGE, transferred to PVDF membrane (BIO-RAD) and probed 
with specific primary and horseradish peroxidase (HRP)-conjugated antibodies. PierceTM ECL Western 
Blotting Substrate (Thermo Fisher Scientific) was used for detection of protein of interest.  
Co-immunoprecipitation 
In brief, cells were washed three times with ice-cold phosphate-buffered saline (PBS) and lysed in lysis 
buffer containing 50 mM Tris pH 7.4, 1% Triton X-100, 0.5 mM EDTA, 0.5 mM EGTA, 150 mM NaCl, 
10% Glycerol, 1 mM phenylmethylsulfonyl fluoride and complete protease inhibitor cocktail (Roche) on 
ice for 30 min. The cell lysates were centrifuged at 15,000 × g for 15 min at 4 °C and 500 µg supernatant 
was precleared by Protein G Agarose Beads (Thermo Fisher Scientific) and incubated with different 
primary antibodies overnight at 4 °C, or incubated with Flag/HA beads (Sigma-Aldrich) directly for 2 h 
at room temperature. Protein G Agarose Beads were added into cell lysates for incubation with rotation at 
4 °C for 1 h. After three washes with 1 mL of lysis buffer, the bound proteins were resolved by SDS-
PAGE and immunoblotted with indicated antibodies. 
RAS-GTP Pull-down  
Active RAS-GTP levels were assessed by Active RAS Pull-Down and Detection Kit (Thermo Fisher 
Scientific) according to the manufacture’s instruction. Specifically, 500 µg whole cell lysates were 
incubated with 30 μL glutathione resin and GST-RBD fusion protein for 1 h at 4 °C to capture active RAS-
GTP proteins. The GST-RBD-bound RAS proteins were recovered by washing and elution. The purified 
NRAS proteins and HA-NRAS recombinant proteins were detected by immunoblot analysis using the 
primary antibodies targeting NRAS (Abcam) and HA tag (Abcam). 
In vitro kinase assay 
Recombinant HA-NRAS proteins were preloaded with GDP, GTP, or GTPγS and subjected to the in vitro 
kinase assay with purified recombinant STK19-Flag proteins in kinase buffer containing 20 mM MnCl2, 
50 mM HEPES (pH 8.0) supplemented with 300 µM AMP and 100 µM ATP (or ATP mixture with γ-32P-
ATP) for 30 min at 30 °C. The phosphorylated HA-NRAS was pulled down by anti-HA beads and 
proceeded for SDS-PAGE. Phosphorylation of NRAS was detected by subsequent immunoblotting and 
autoradiography.  
Mass spectrometry 
Liquid chromatography/tandem mass spectrometry was performed by Taplin Biological Mass 
Spectrometry Facility, Harvard Medical School. For identification of STK19-interacting proteins, cell 
lysates of SK-MEL-2 overexpressing human recombinant Flag-tagged STK19 were isolated by anti-Flag 
magnetic agarose beads. For identification of phosphorylated amino acids in NRAS by STK19, HA-NRAS 
protein was pulled down by anti-HA magnetic agarose beads after in vitro kinase reaction with STK19-
Flag. The prepared protein samples were incubated with sample buffer for 5 min at 100 °C, and then 
separated by SDS-PAGE. The gel was immersed in staining solution (0.3% Coomassie blue, 45% 
methanol, 10% glacial acetic acid and 45% dH2O) on shaker for 30 min, followed by incubation in 
destaining solution (20% methanol, 10% glacial acetic acid, and 70% dH2O) on the shaker overnight. The 
bands were excised and sent to Taplin Biological Mass Spectrometry Facility in Harvard Medical School 
for protein identification and protein phosphorylation identification. 
Colony formation and cell proliferation assays 
The colony formation assay for hTERT/p53DD/CDK4(R24C) melanocytes were performed as described 
before. Briefly, hTERT/p53DD/CDK4(R24C) melanocytes infected with indicated plasmids were plated 
into 6-well plate at 2,500 cells per well and cultured for 14 days. The colonies were fixed with 10% (v/v) 
methanol for 15 min and stained with 5% Giemsa (Sigma) for 30 min for colony visualization. Cell 
proliferation rates were determined by CyQUANTTM NF Cell Proliferation Assay Kit (Invitrogen) 
according to the manufacturer’s protocol. In brief, cells were plated at density of 100-500 cells per well 
in a 96-well microplate. After indicated treatment for 4 days, CyQUANT® NF dye solution was added to 
each well to generate fluorescence readout after binding with DNA. The fluorescence intensity was 
measured using a fluorescence microplate reader with 485/520 nm filter set. The relative cell number 
stands for fold change in relation to the cell number of control group. 
Melanin staining 
The melanin staining in mouse ears was performed with the Fontana-Masson kit (Abcam, ab150669) 
following the manufacturer’s protocol. Briefly, the sectioned ear tissues were hydrated and incubated 
successively in warmed ammoniacal silver solution for 30 min, gold chloride solution (0.2%) at room 
temperature for 30 s, sodium thiosulfate solution (5%) at room temperature for 1 min, and nuclear fast red 
solution for 5 min. After dehydration, the slide was mounted and observed with an Olympus Inverted 
microscope (Cellular imaging core, Boston University). 
Optimization and validation of the STK19 kinase assay 
The optimal conditions of the STK19 enzyme and the ATP concentrations in the 96-well format kinase 
assay were first determined using Promega ADP-Glo® kinase assay according to the manufacture’s 
protocol. For the enzyme concentration and reaction time optimization, Flag-tagged STK19 at various 
concentrations (ranging from 0.2 to 400 nM), ATP (100 μM) and the substrate HA-tagged GTP-preloaded 
NRAS (1 μM) were added to 96-well white solid plates (15 μL volume) for 0 to 40 min in the kinase 
buffer. The kinase reaction was stopped by ADP-GloTM Reagent and the ADP generated in the kinase 
reaction was converted to ATP for luciferase assay. Phosphorylation of HA-tagged NRAS was quantified 
based on the luminescence readout measured with Tecan Infinite® M1000 Microplate Reader. The 
optimal amount of STK19 is the minimal amount that produces luminescence within the linear portion of 
the kinase titration curve and generates an adequate signal-to-background ratio. The optimal kinase 
reaction time was defined as the point at which the EC50 from the enzyme titration no longer changes. We 
finally chose 12.5 nM STK19 and 15 min as the optimal kinase concentration and reaction time for the 
kinase assay. The ATP titration was conducted with STK19 kinase using the enzyme concentration 
previously determined, and the kinase assays were performed at ATP concentrations ranging from 0.5 μM 
to 200 μM. The apparent ATP Km(app) was calculated by fitting data using the Michaelis-Menten 
equation. The ATP concentration of 6.36 μM Km(app) for STK19 was determined to show a 50% change 
between the maximum and minimum phosphorylated NRAS levels.  
  Assay quality was determined using the Z-factor, indicating the quality of an assay. Z-factors of 0.5 or 
greater indicate an excellent assay. The assay optimization procedure uses the wells in the row that contain 
no kinase as the 100% inhibition control wells and each of the wells in the row containing STK19 as the 
0% inhibition control wells. The Z-factor value was calculated using the following equation: 
                 Z-factor = 1 – 3 × (σ0%Inhibition + σ100%Inhibition) / (µ0%Inhibition - µ100%Inhibition), 
where σ represents standard deviation and µ represents the mean value of the luminescence. The Z-factor 
was 0.703 for Flag-tagged STK19, confirming the optimization of the enzyme concentration, the reaction 
time and the ATP concentration. 
Procedures for chemical synthesis of ZT-12-037-01 (1a) 
 
 
 
 
Reagents and conditions: a) 1-isopropylpiperidin-4-amine, DMF, K2CO3, room temperature, 6 h; b) 
cyclopropanamine, TFA, MW, 110 ℃, 1 h. 
 
2-chloro-N-(1-isopropylpiperidin-4-yl)-6,7-dime thoxyquinazolin-4-amine (IM)  
To a stirred solution of 2,4-dichloro-6,7-dimethoxyquinazoline (259.1 mg, 1 mmol) in DMF (5 mL) was 
added K2CO3 (207.03 mg, 1.5 mmol) and 1-isopropylpiperidin-4-amine (170.7 mg, 1.2 mmol). After 
stirring for 6 h, the reaction was quenched with water and extracted with EtOAc (3 × 20 mL). The 
combined organic layers were dried over anhydrous Na2SO4, filtered, and concentrated under reduced 
pressure. The crude solid was purified by silica gel chromatography [MeOH (1.75 N NH3)/CH2Cl2 = 1: 
10] to afford compound 1 as white crystals (300 mg, 82.2% yield). 1H NMR (600 MHz, CDCl3) δ 7.13 (s, 
1H), 6.77 (s, 1H), 4.34 – 4.18 (m, 1H), 4.01 (s, 3H), 3.98 (s, 3H), 2.94 – 2.88 (m, 2H), 2.79 (p, J = 6.5 Hz, 
1H), 2.46 – 2.32 (m, 2H), 2.22 – 2.13 (m, 2H), 1.64 – 1.56 (m, 2H), 1.08 (d, J = 6.6 Hz, 6H). MS (ESI) 
m/z: 365[M+H]+. 
N2-cyclopropyl-N4-(1-isopropylpiperidin-4-yl)-6,7-dimethoxyquinazoline-2,4-diamine (ZT-12-037-
01, 1a) 
The intermediate IM (36.5 mg, 0.1 mmol) was dissolved in cyclopropanamine (0.5 mL) and treated with 
trifluoroacetic acid (74.3 uL, 1 mmol). The solution was heated in microwave synthesizer (Initiator™) at 
110 °C for 1 h, then it was concentrated under reduced pressure. The resulting residue was purified by 
preparative HPLC to yield the creamy white compound (31.3 mg, 81.2%). 1H NMR (600 MHz, CDCl3) δ 
7.28 (s, 1H), 6.85 (s, 1H), 4.49 – 4.32 (m, 1H), 3.97 (s, 3H), 3.93 (s, 3H), 3.40 – 3.28 (m, 2H), 3.29 – 3.17 
(m, 1H), 2.85 – 2.74 (m, 1H), 2.78 – 2.64 (m, 2H), 2.35 – 2.27 (m, 2H), 2.28 – 2.14 (m, 2H), 1.31 – 1.23 
(m, 6H), 0.81 – 0.70 (m, 2H), 0.72 – 0.61 (m, 2H). 13C NMR (150 MHz, CDCl3) δ 159.3, 156.2, 155.0, 
147.3, 117.9, 116.0, 103.2, 102.3, 56.8, 56.7, 56.7, 47.8, 29.3, 23.9, 17.5, 6.8. MS (ESI) m/z: 386[M+H]+. 
HRMS (ESI) calculated for C21H32N5O2 [M+H]+, 386.2556; found, 386.2551. 
Differential scanning fluorimetry (DSF) assay 
The thermal denaturation of STK19-Flag was determined by DSF assay using Protein Thermal ShiftTM 
Dye Kit (Thermal Fisher Scientific). In brief, the purified recombinant protein was diluted to a final 
concentration of 10 μM in 100 mM Tris buffer (pH 8.0). 1a (final concentration at 100 μM) was added to 
obtain 20 μL of assay volume. Heat gradient from 25 °C (100%) to 99 °C (1%) was conducted in 
QuantStudio 12K Flex Real-Time PCR System. The melt curve was recorded and the melting temperature 
was determined using the inflection points of the plots of d(RFU)/dT. 
In vivo proliferation and apoptosis assay 
The xenograft tumor tissues were isolated and mounted in O.C.T. embedding compound (Fisher 
Healthcare) and cut into 8 μm sections (Dermpath core facility, Boston University). For immunostaining, 
after thawing and rehydration, the slides were blocked with 0.1% Tween-20 and 5% normal goat serum 
(Jackson ImmunoResearch) in PBS for 1 h at room temperature for nonspecific staining, and incubated 
with primary antibodies against Ki67 and cleaved caspase 3 overnight at 4 °C. Then, slides were incubated 
with fluorescent-labelled corresponding secondary antibodies for 1 h at room temperature. The slides were 
mounted with ProLong Gold Antifade Mountant with DAPI (Thermo Fisher Scientific). Images were 
taken with a laser scanning confocal microscope Leica SP5 (Cellular imaging core, Boston University). 
 
QUANTIFICATION AND STATISTICAL ANALYSIS  
All quantitative data were presented as the mean ± SD or SEM of at least three independent experiments 
by Student’s paired or unpaired two-tailed t-test or two-way ANOVA, as appropriate. (*P < 0.05, **P < 
0.01, ***P < 0.001, n.s., not significant). For survival analysis, the Kaplan–Meier survival curves were 
compared using the log–rank test. Analyses were performed using GraphPad Prism V7. 
 














